Humanized Mouse Models of Infection.

Dane Parker
Author Information
  1. Dane Parker: Department of Pediatrics, Columbia University, New York, NY, USA.

Abstract

is a successful human pathogen that has adapted itself in response to selection pressure by the human immune system. A commensal of the human skin and nose, it is a leading cause of several conditions: skin and soft tissue infection, pneumonia, septicemia, peritonitis, bacteremia, and endocarditis. Mice have been used extensively in all these conditions to identify virulence factors and host components important for pathogenesis. Although significant effort has gone toward development of an anti-staphylococcal vaccine, antibodies have proven ineffective in preventing infection in humans after successful studies in mice. These results have raised questions as to the utility of mice to predict patient outcome and suggest that humanized mice might prove useful in modeling infection. The development of humanized mouse models of infection will allow us to assess the contribution of several human-specific virulence factors, in addition to exploring components of the human immune system in protection against infection. Their use is discussed in light of several recently reported studies.

Keywords

References

  1. Cell Host Microbe. 2013 Jun 12;13(6):759-72 [PMID: 23768499]
  2. FASEB J. 2009 Oct;23(10):3393-404 [PMID: 19525403]
  3. JAMA. 2013 Apr 3;309(13):1368-78 [PMID: 23549582]
  4. PLoS Pathog. 2014 Feb 13;10(2):e1003871 [PMID: 24550724]
  5. Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1167-72 [PMID: 25092317]
  6. Nat Rev Microbiol. 2008 Feb;6(2):132-42 [PMID: 18197169]
  7. BMC Infect Dis. 2012 Feb 20;12:45 [PMID: 22348549]
  8. Nat Med. 2007 Dec;13(12):1405-6 [PMID: 18064027]
  9. Ann N Y Acad Sci. 2015 Apr;1342:29-36 [PMID: 25678404]
  10. Nat Rev Microbiol. 2014 Jan;12(1):49-62 [PMID: 24336184]
  11. MBio. 2016 Feb 09;7(1):e01939-15 [PMID: 26861017]
  12. Nat Rev Immunol. 2012 Nov;12(11):786-98 [PMID: 23059428]
  13. Nat Med. 2004 Aug;10(8):842-8 [PMID: 15247912]
  14. Emerg Infect Dis. 2010 May;16(5):797-803 [PMID: 20409369]
  15. Lancet Infect Dis. 2013 Jul;13(7):566 [PMID: 23809217]
  16. J Immunol. 2012 Jun 15;188(12):6145-55 [PMID: 22611244]
  17. Clin Infect Dis. 1999 Nov;29(5):1128-32 [PMID: 10524952]
  18. Blood. 2010 Jul 15;116(2):193-200 [PMID: 20404133]
  19. Int J Hyg Environ Health. 2008 Mar;211(1-2):205-12 [PMID: 17692566]
  20. Lancet. 2002 Mar 2;359(9308):753-9 [PMID: 11888586]
  21. Emerg Infect Dis. 2006 Jun;12(6):894-9 [PMID: 16707043]
  22. PLoS One. 2015 Jun 22;10(6):e0129825 [PMID: 26098918]
  23. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3507-12 [PMID: 23401516]
  24. Cell Host Microbe. 2010 Dec 16;8(6):544-50 [PMID: 21147468]
  25. Blood. 2011 Sep 15;118(11):3119-28 [PMID: 21791433]
  26. PLoS Pathog. 2015 Nov 30;11(11):e1005292 [PMID: 26618545]
  27. PLoS Pathog. 2013 Feb;9(2):e1003143 [PMID: 23436994]
  28. J Exp Med. 1990 Oct 1;172(4):1055-63 [PMID: 2212942]
  29. Clin Infect Dis. 2011 Dec;53(12):1199-207 [PMID: 22021918]
  30. J Clin Microbiol. 2003 Nov;41(11):5113-20 [PMID: 14605147]
  31. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13823-8 [PMID: 22869727]
  32. Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5587-92 [PMID: 20231457]
  33. Crit Care. 2006;10(3):R97 [PMID: 16808853]
  34. J Infect Dis. 2015 Aug 1;212(3):435-44 [PMID: 25657257]
  35. Clin Infect Dis. 2005 Jan 1;40(1):100-7 [PMID: 15614698]
  36. Virulence. 2016 Dec 7;:1-12 [PMID: 27925510]
  37. Blood. 2005 Sep 1;106(5):1565-73 [PMID: 15920010]
  38. J Clin Invest. 1959 Jan;38(1 Part 2):213-65 [PMID: 13620784]
  39. Nat Med. 2011 Aug 21;17(9):1142-6 [PMID: 21857652]
  40. Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10794-9 [PMID: 23754403]
  41. JAMA. 2007 Oct 17;298(15):1763-71 [PMID: 17940231]
  42. MMWR Morb Mortal Wkly Rep. 2009 Oct 2;58(38):1071-4 [PMID: 19798021]
  43. Nat Rev Genet. 2003 Mar;4(3):195-205 [PMID: 12610524]
  44. PLoS Med. 2006 Feb;3(2):e76 [PMID: 16401173]
  45. Immunity. 2006 Jan;24(1):79-91 [PMID: 16413925]
  46. Pediatrics. 2008 Oct;122(4):805-11 [PMID: 18829805]
  47. Am J Respir Crit Care Med. 2012 Nov 1;186(9):824-9 [PMID: 22798317]
  48. Front Cell Infect Microbiol. 2012 Feb 22;2:16 [PMID: 22919608]
  49. Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):E345 [PMID: 25540422]
  50. Clin Microbiol Rev. 2013 Jul;26(3):422-47 [PMID: 23824366]
  51. Infect Immun. 2012 Oct;80(10):3721-32 [PMID: 22802349]
  52. J Infect Dis. 2016 Jun 15;213(12):1990-5 [PMID: 26908735]
  53. Emerg Infect Dis. 2007 Dec;13(12):1840-6 [PMID: 18258033]
  54. Am J Pathol. 2012 Oct;181(4):1206-14 [PMID: 22902429]
  55. Clin Microbiol Infect. 2013 Jun;19(6):528-36 [PMID: 22712729]
  56. Nat Med. 2015 Aug;21(8):869-79 [PMID: 26168294]
  57. Infect Immun. 2014 Sep;82(9):3588-98 [PMID: 24914221]
  58. Virulence. 2013 Nov 15;4(8):666-8 [PMID: 24165206]
  59. Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2390-5 [PMID: 21262803]
  60. Nat Biotechnol. 2014 Apr;32(4):364-72 [PMID: 24633240]
  61. Evol Med Public Health. 2016 May 21;2016(1):170-6 [PMID: 27121451]
  62. Toxins (Basel). 2015 May 22;7(5):1821-36 [PMID: 26008236]
  63. JAMA. 2013 Jan 16;309(3):275-82 [PMID: 23321766]
  64. Clin Infect Dis. 2011 Jul 15;53(2):144-9 [PMID: 21690621]
  65. Infect Immun. 2007 Feb;75(2):1040-4 [PMID: 17101657]
  66. JAMA. 2003 Mar 19;289(11):1377 [PMID: 12636454]
  67. MBio. 2015 Apr 21;6(2):null [PMID: 25900653]
  68. Comp Med. 2007 Dec;57(6):563-9 [PMID: 18246868]
  69. Nat Cell Biol. 2007 Sep;9(9):993-9 [PMID: 17762889]
  70. J Infect Dis. 2017 Mar 1;215(5):824-829 [PMID: 28035011]
  71. Infect Immun. 1991 Aug;59(8):2615-23 [PMID: 1855981]
  72. Eur J Immunol. 2009 Aug;39(8):2136-45 [PMID: 19572320]
  73. Lancet Infect Dis. 2013 Jan;13(1):43-54 [PMID: 23103172]
  74. J Infect Dis. 2008 Oct 1;198(7):962-70 [PMID: 18710327]
  75. Blood. 2006 Jul 15;108(2):487-92 [PMID: 16410443]
  76. Antimicrob Agents Chemother. 2009 May;53(5):1874-83 [PMID: 19223616]
  77. Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13218-23 [PMID: 21788509]
  78. PLoS Pathog. 2010 Aug 05;6(8):e1001036 [PMID: 20700445]
  79. Clin Microbiol Infect. 2010 Nov;16(11):1644-8 [PMID: 20969671]
  80. J Infect Dis. 2006 Apr 1;193(7):996-1004 [PMID: 16518762]
  81. Eur J Immunol. 1996 May;26(5):1074-82 [PMID: 8647170]
  82. Curr Opin Immunol. 2013 Jun;25(3):403-9 [PMID: 23628166]
  83. J Immunol. 2005 May 15;174(10):6477-89 [PMID: 15879151]
  84. Science. 2007 Feb 23;315(5815):1130-3 [PMID: 17234914]
  85. J Immunol Methods. 2014 Aug;410:3-17 [PMID: 24607601]
  86. PLoS One. 2010 Jan 14;5(1):e8705 [PMID: 20090931]
  87. J Infect Dis. 2009 Sep 1;200(5):724-34 [PMID: 19604047]
  88. J Immunol. 2012 Oct 15;189(8):4040-6 [PMID: 22962685]
  89. Lancet. 2004 Aug 21-27;364(9435):703-5 [PMID: 15325835]
  90. Pediatr Infect Dis J. 2005 Jul;24(7):617-21 [PMID: 15999003]
  91. J Infect Dis. 2016 Sep 16;:null [PMID: 27638942]
  92. Nat Biotechnol. 2015 Oct;33(10):1103-8 [PMID: 26414350]
  93. Ann Intern Med. 2006 Mar 7;144(5):309-17 [PMID: 16520471]
  94. J Infect Dis. 2008 May 1;197(9):1226-34 [PMID: 18422434]
  95. PLoS One. 2011 Mar 31;6(3):e18045 [PMID: 21483851]

Grants

  1. R01 HL134870/NHLBI NIH HHS

Word Cloud

Created with Highcharts 10.0.0infectionhumanskinseveralmicehumanizedmousesuccessfulimmunesystempneumoniavirulencefactorscomponentsdevelopmentstudiespathogenadaptedresponseselectionpressurecommensalnoseleadingcauseconditions:softtissuesepticemiaperitonitisbacteremiaendocarditisMiceusedextensivelyconditionsidentifyhostimportantpathogenesisAlthoughsignificanteffortgonetowardanti-staphylococcalvaccineantibodiesprovenineffectivepreventinghumansresultsraisedquestionsutilitypredictpatientoutcomesuggestmightproveusefulmodelingmodelswillallowusassesscontributionhuman-specificadditionexploringprotectionusediscussedlightrecentlyreportedHumanizedMouseModelsInfectionStaphylococcusaureuslungmodelsepsis

Similar Articles

Cited By